StreetInsider.com News Articles

Personalis (PSNL) PT Lowered to $10 at Morgan Stanley

Wed, 04 Mar 2026 17:20:37 -0500

Morgan Stanley analyst Kallum Titchmarsh lowered the price target on Personalis (NASDAQ: PSNL) to $10.00 (from $11.00) while maintaining a Equalweight rating.

Personalis (PSNL) PT Raised to $12 at Needham

Fri, 27 Feb 2026 06:17:28 -0500

(Updated - February 27, 2026 6:17 AM EST)

Needham analyst Mike Matson raised the price target on Personalis (NASDAQ: PSNL) to $12.00 (from $10.00) while maintaining a Buy rating.

The analyst commented: "PSNL's 4Q25 revenue was in line with its preannouncement, and management provided 2026 revenue guidance that was below consensus. Revenue growth improved to 3% in 4Q25 from (44%) in 3Q25 as growth from biopharma, clinical diagnostics, and VA MVP all improved. Importantly, PSNL performed 6,183 molecular tests in 4Q25 (up 41% sequentially and ~330% Y/Y). PSNL has been awarded Medicare reimbursement for breast cancer and lung cancer and is awaiting

Personalis (PSNL) PT Raised to $12 at Needham

Fri, 27 Feb 2026 06:17:28 -0500

(Updated - February 27, 2026 6:17 AM EST)

Needham analyst Mike Matson raised the price target on Personalis (NASDAQ: PSNL) to $12.00 (from $10.00) while maintaining a Buy rating.

BTIG Reiterates Buy Rating on Personalis (PSNL)

Fri, 27 Feb 2026 06:07:38 -0500

BTIG analyst Mark Massaro reiterated a Buy rating and $13.00 price target on Personalis (NASDAQ: PSNL).

The analyst commented: "Personalis signaled a good deal of confidence on its Q4 call and plans to expand the size of its direct sales force for its MRD business (from 10 to 20 reps this year), who will work in tandem with its large commercial partner, Tempus (TEM, Buy, $90). We think PSNL is likely to obtain Medicare coverage from Palmetto GBA for its pan-cancer immunotherapy monitoring indication roughly by mid-year 2026, which would mark its third coverage decision for its NeXT Personal ultra-sensitive MRD

Form S-8 Personalis, Inc.

Thu, 26 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260226/26072781.html

Form S-8 Personalis, Inc.

Thu, 26 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260226/26072781.html

Personalis, Inc. (PSNL) Tops Q4 EPS by 4c, provides guidance

Thu, 26 Feb 2026 16:22:08 -0500

Personalis, Inc. (NASDAQ: PSNL) reported Q4 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $17.55 million.

GUIDANCE:

Personalis, Inc. sees FY2026 revenue of $78-80 million, versus the consensus of $81.679 million.

For earnings history and earnings-related data on Personalis, Inc. (PSNL) click here.

Personalis, Inc. (PSNL) Tops Q4 EPS by 4c, provides guidance

Thu, 26 Feb 2026 16:22:08 -0500

GUIDANCE:

Personalis, Inc. sees FY2026 revenue of $78-80 million, versus the consensus of $81.679 million.

For earnings history and earnings-related data on Personalis, Inc. (PSNL) click here.

Form 10-K Personalis, Inc. For: Dec 31

Thu, 26 Feb 2026 16:16:00 -0500

http://archive.fast-edgar.com/20260226/AU2LB22CZZ2RKTZU22ZI2ZYKGQMRZZ22Z286

Filed on: February 26, 2026

Form 10-K Personalis, Inc. For: Dec 31

Thu, 26 Feb 2026 16:16:00 -0500

http://archive.fast-edgar.com/20260226/AU2LB22CZZ2RKTZU22ZI2ZYKGQMRZZ22Z286

Filed on: February 26, 2026

Form 8-K Personalis, Inc. For: Feb 26

Thu, 26 Feb 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260226/26070548.html

Form 8-K Personalis, Inc. For: Feb 26

Thu, 26 Feb 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260226/26070548.html

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights